HomeInsightsStock Comparison

Bliss Gvs Pharma Ltd vs Windlas Biotech Ltd Stock Comparison

Bliss Gvs Pharma Ltd vs Windlas Biotech Ltd Stock Comparison

Last Updated on: Apr 29, 2025

Key Highlights

  • The Latest Trading Price of Bliss GVS Pharma Ltd is ₹ 122.55 as of 29 Apr 10:57.
  • The P/E Ratio of Bliss GVS Pharma Ltd changed from 10.7 on March 2020 to 15.6 on March 2024 . This represents a CAGR of 7.83% over 5 yearsThe P/E Ratio of Windlas Biotech Ltd changed from 12 on March 2022 to 18.3 on March 2024 . This represents a CAGR of 15.10% over 3 years.
  • The Market Cap of Bliss GVS Pharma Ltd changed from ₹ 1039 crore on March 2020 to ₹ 1179 crore on March 2024 . This represents a CAGR of 2.55% over 5 yearsThe Market Cap of Windlas Biotech Ltd changed from ₹ 457.9 crore on March 2022 to ₹ 1065 crore on March 2024 . This represents a CAGR of 32.52% over 3 years.
  • The revenue of Bliss GVS Pharma Ltd for the Dec '24 is ₹ 225.68 crore as compare to the Sep '24 revenue of ₹ 222.72 crore. This represent the growth of 1.33% The revenue of Windlas Biotech Ltd for the Dec '24 is ₹ 199.13 crore as compare to the Sep '24 revenue of ₹ 191.84 crore. This represent the growth of 3.8%.
  • The ebitda of Bliss GVS Pharma Ltd for the Dec '24 is ₹ 45.05 crore as compare to the Sep '24 ebitda of ₹ 46.51 crore. This represent the decline of -3.14% The ebitda of Windlas Biotech Ltd for the Dec '24 is ₹ 28.74 crore as compare to the Sep '24 ebitda of ₹ 27.89 crore. This represent the growth of 3.05%.
  • The net profit of Bliss GVS Pharma Ltd changed from ₹ 14.37 crore to ₹ 25.8 crore over 7 quarters. This represents a CAGR of 39.71% The net profit of Windlas Biotech Ltd changed from ₹ 12.07 crore to ₹ 15.58 crore over 7 quarters. This represents a CAGR of 15.70% .
  • The Dividend Payout of Bliss GVS Pharma Ltd changed from 5.58 % on March 2020 to 10.34 % on March 2024 . This represents a CAGR of 13.13% over 5 yearsThe Dividend Payout of Windlas Biotech Ltd changed from 19.79 % on March 2022 to 19.68 % on March 2024 . This represents a CAGR of -0.19% over 3 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Bliss GVS Pharma Ltd

  • Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984.
  • The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006. The Company, founded in 1984 with the objective of ensuring healthcare access worldwide, is one of the pharmaceutical industries' fastest-growing businesses.
  • The Company has a robust portfolio of more than 250 products and is a global leader in the dosage forms for suppositories and pessaries.
  • It has a strong foothold in Sub Saharan Africa.
  • The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

About Windlas Biotech Ltd

  • Windlas Biotech Limited (formerly known as Windlas Biotech Private Limited) was incorporated in 2001.
  • The Company converted from a Private Limited Company to a Public Limited Company and the name of the Company was changed to Windlas Biotech Limited'.
  • A fresh Certificate of Incorporation dated April 15, 2021, granted by the Registrar of Companies, Uttarakhand at Dehradun. The Company is engaged in manufacturing and trading of pharmaceutical products.
  • TheIR manufacturing facilities are located at Dehradun in Uttarakhand.
  • It also has a sales force and distribution network spread across 14 states.

Bliss GVS Pharma Ltd News Hub

News

Bliss GVS Pharma schedules board meeting

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 28 Januar...

Read more

22 Jan 2025 09:41

News

Bliss GVS Pharma allots 34,250 equity shares under ESOP

Bliss GVS Pharma has allotted 34,250 equity shares under ESOP on 06 December 2024. With th...

Read more

06 Dec 2024 19:02

News

Bliss GVS Pharma soars after manufacturing units get GMP certificate from Romania medical authority

In a regulatory filing made on Saturday, the company informed that its manufacturing facil...

Read more

25 Nov 2024 09:40

News

Bliss GVS Pharma's manufacturing facilities complete EU GMP inspection

Bliss GVS Pharma announced that the company's manufacturing facility situated at Plot No. ...

Read more

23 Nov 2024 15:02

News

Bliss GVS Pharma to table results

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 24 Octobe...

Read more

18 Oct 2024 10:48

News

Bliss GVS Pharma allots 1.57 lakh equity shares under ESOP

Bliss GVS Pharma has allotted 157,550 equity shares under ESOP on 04 October 2024. With th...

Read more

04 Oct 2024 18:37

Windlas Biotech Ltd News Hub

News

Windlas Biotech receives affirmation in credit ratings from ICRA

Windlas Biotech has received reaffirmation in credit ratings from ICRA at ICRA A+; Stable/...

Read more

08 Apr 2025 15:08

News

Windlas Biotech to hold board meeting

Windlas Biotech will hold a meeting of the Board of Directors of the Company on 11 Februar...

Read more

04 Feb 2025 10:43

News

Windlas Biotech receives GMP certification for its new state-of-the-art injectable facility

Windlas Biotech announced that it has received Good Manufacturing Practices (GMP) certific...

Read more

10 Jan 2025 15:42

News

Windlas Biotech gains after receiving GMP certification for new injectable facility

The certification, granted by the Food Safety & Drugs Administration Authority of Uttarakh...

Read more

10 Jan 2025 13:05

News

Windlas Biotech allots 59,000 equity shares under ESOS

Windlas Biotech has allotted 59,000 equity shares under ESOS on 03 January 2025. Powered b...

Read more

03 Jan 2025 20:23

News

Windlas Biotech announces board meeting date

Windlas Biotech will hold a meeting of the Board of Directors of the Company on 12 Novembe...

Read more

06 Nov 2024 13:51

SWOT Analysis Of Windlas Biotech Ltd

Strength

5

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Bliss GVS Pharma Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Windlas Biotech Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Bliss GVS Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Bliss GVS Pharma Ltd and Windlas Biotech Ltd

Which company has a larger market capitalization, Bliss GVS Pharma Ltd or Windlas Biotech Ltd?

Market cap of Bliss GVS Pharma Ltd is 1,282 Cr while Market cap of Windlas Biotech Ltd is 2,066 Cr

What are the key factors driving the stock performance of Bliss GVS Pharma Ltd and Windlas Biotech Ltd?

The stock performance of Bliss GVS Pharma Ltd and Windlas Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bliss GVS Pharma Ltd and Windlas Biotech Ltd?

As of April 29, 2025, the Bliss GVS Pharma Ltd stock price is INR ₹121.7. On the other hand, Windlas Biotech Ltd stock price is INR ₹988.65.

How do dividend payouts of Bliss GVS Pharma Ltd and Windlas Biotech Ltd compare?

To compare the dividend payouts of Bliss GVS Pharma Ltd and Windlas Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions